Vertex Pharmaceuticals Non-GAAP EPS of $3.60 beats by $0.10, revenue of $2.2B beats by $70M
Vertex Pharmaceuticals press release  (NASDAQ:VRTX): Q2  Non-GAAP EPS of $3.60  beats by $0.10.
Revenue of $2.2B (+22.9% Y/Y)  beats by $70M.
Cash, cash equivalents and marketable securities as of June 30, 2022 were $9.3 billion, an increase of approximately $1.7 billion compared to December 31, 2021. The increase was primarily driven by strong revenue growth and operating cash flow.
Shares -1%.
Outlook: Vertex is raising its full year 2022 product revenue guidance to $8.6 to $8.8 billion vs. prior guidance of $8.4 to $8.6 billion vs. consensus of $8.58B